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Abstract
The importance of obtaining an accurate and early diagnosis for Alzheimer’s disease is now becoming recognized. Non-
pharmacological as well as pharmacological therapies can be best initiated once a diagnosis is obtained. Biochemical markers
to identify Alzheimer’s disease have been sought for many years, with many candidates proposed. Recently criteria were
established to evaluate putative diagnostic tests. Several biomarkers now show utility in identifying those with Alzheimer’s
disease. The ApoE e4 allele, while a risk factor rather than a deterministic gene, in the context of an individual with suspicion
of AD has a positive predictive value of 94^98% and may come to have utility in predicting response to certain classes of
pharmacological agents. Independent groups have shown that the markers in cerebrospinal fluid tau and Ab42 are,
respectively, elevated and reduced in patients with AD versus other patient groups and that the lumbar puncture itself is
usually well tolerated. For early-onset AD, sequencing presenilin 1 has come into use and the positive frequency is similar to
that found in other genetic-based laboratory tests. ß 2000 Elsevier Science B.V. All rights reserved.
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1. The importance of diagnosis
While Alzheimer’s disease (AD) is the most com-
mon cause of dementia, accounting for about 2/3 of
all dementia cases, it is only one of about 70 di¡erent
disorders that may cause dementia. Di¡erential diag-
nosis is di⁄cult and conventional AD diagnoses have
been reported as being wrong approximately 15% of
the time from tertiary care centers. A number of
these causes of dementia are currently reversible, in-
cluding subdural hematomas, drug interaction, vita-
min de¢ciencies, and low grade carbon monoxide
poisoning. The more common non-AD causes of de-
mentia are depression, parkinsonian, frontotemporal
and vascular dementias. Each of these conditions has
unique treatment and management strategies, and
therefore it is of key importance to distinguish be-
tween these di¡ering disorders as early and accu-
rately as possible.
Compared to other disease areas, the ¢eld of de-
mentia oftentimes stimulates questions concerning
the value of carrying out a diagnostic workup. It is
sometimes said that since there is no cure or e¡ective
therapy, that there is no point spending time and
e¡ort in trying to identify the cause of the individu-
al’s disorder. A re¢nement of this argument is that,
once potential treatable causes of dementia are ruled-
out, again there is no point in further classi¢cation.
The argument is extended to comments that since an
accurate diagnosis can only be made at autopsy,
there is no reason to worry the person or the family
by attaching a disease with a label that strikes fear
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into many. Many of these types of comments are
reminiscent of the approach taken until recently to
patients with cancer. Indeed, until quite recently, it
was possible for individuals in the UK to never know
that they were dying of cancer. Clearly the way med-
icine is practised with respect to disclosure has
changed. The last bastion of this approach is found
in the dementia ¢eld. A study in a community-based
retirement community showed that 80% of those
who responded would prefer to know if they had
AD [1].
The arguments concerning the pointlessness of car-
rying out a diagnostic workup are quite fallacious. In
dementia, as in all other branches of medicine, the
certainty of a diagnosis has an important impact on
the management of the patient. While AD cannot be
cured, there is symptomatic treatment available, and
the ¢rst drugs for the temporary improvement of
cognition and behavior are now licensed by the US
Food and Drug Administration. Often overlooked,
however, are the non-pharmacological interventions
that can assist both the patient and the caregiver in
tackling the day-to-day issues in living with this dis-
order. For example, quite simple techniques now in
use can be used to help the patients improve their
ability to dress themselves; and in some cases enable
patients to dress themselves with only guidance.
Behavioral therapies, while certainly not a cure,
can have a quick practical impact as they have
been shown to reduce many of the more disruptive
behavior found in these patients, such as screaming,
wandering or hitting [2]. Prior to the adoption of
behavior management techniques, institutions would
have typically attempted to control these behaviors
by use of antipsychotic drugs or physical restraint,
measures that increase the patient’s agitation and
may further worsen their condition. There are, there-
fore, signi¢cant non-pharmacological interventions
possible that require as accurate a diagnosis as pos-
sible of the underlying disorder. Many times over-
looked are the social issues concerned with the dis-
ease. Uniquely, dementia has a feature that is not
replicated elsewhere. If a diagnosis is not provided
until late in the disease process, the patient may be
past the point at which they retain su⁄cient cogni-
tive ability to participate in their own medical treat-
ment and planning. This can deprive the individual
of including their desires and wishes in dealing with
the disease and place additional responsibilities on
the caregiver. A diagnosis will enable the patients
and their family to deal with legal and estate matters
in a planned manner, to plan future care needs and
address safety concerns, not the least of which in the
US are the issues surrounding patients with AD con-
tinuing to drive.
One of the key features of AD is the involvement
of family members and typically a key individual as
caregiver. Up to 3/4 of caregivers can develop signs
of major depression, however, when involved in sup-
port services and training for managing behavioral
problems, caregivers were found to respond favor-
ably, and in one study delayed placing the patient
in nursing homes by an average of one year. Some
physicians indicate that unless a diagnosis is carried
out and discussed with the caregiver, the caregiver
may be reluctant to participate in support activities
and they may not feel that it is appropriate to join in
with such activities. This denies the caregiver the
opportunity to come to terms with the disease, plan
for the future, and learn best how to cope with the
patient. One caregiver remarked that if she had
known what was wrong with her father, she would
not have gone ahead and bought a bigger house that
was not suitable in which to look after him. This
disease will have a major e¡ect on the lives of the
caregivers, and they want to know what to expect as
well as the patient.
Intellectual decline is well recognized as a core
feature of AD. What are often overlooked are the
neuropsychiatric behavioral disturbances. It has been
commented that AD is the most common psychiatric
disorder after schizophrenia. These disturbances in-
clude personality disorders, delusions, hallucinations,
mood abnormalities, disorders of sleep, change in
appetite, altered sexual function, and disturbed psy-
chomotor activity [3]. These neuropsychiatric distur-
bances of AD can be the most disabling consequen-
ces of the disease and are more troublesome to the
family than the cognitive dysfunction. The neuro-
psychiatric disturbances are a typical feature of the
disease, with 50% of AD patients have delusions.
Delusional disturbances, for example, are often treat-
able with conventional neuroleptic agents and the
therapy may well decrease the associated aggression
and agitation, improving the quality of life for the
patient and their caregiver. The di¡ering causes of
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dementia have a di¡erent frequency distribution of
neuropsychiatric disturbances. It is crucial, not only
to treat these disturbances, but also to know based
on the speci¢c disease, the most likely panoply of
disturbances that will be encountered and to provide
training for the caregiver in management of the pa-
tient. As with any disorder, prior to the use of com-
plex pharmacological interventions, it is key to estab-
lish the most accurate diagnosis possible as well as
identify any concurrent illnesses.
While it is conventionally considered that the ‘gold
standard’ for a diagnosis of AD are the neuropathol-
ogy ¢ndings at autopsy, there remain di¡erences of
opinion as to how to interpret the neuropathological
data in the event of concomitant diseases, a not un-
common feature of AD. Two drugs, both acetylcho-
linesterase inhibitors, are currently approved by
FDA for the direct treatment of AD. These agents,
however have side e¡ects and the indiscriminate use
of these drugs in all dementia patients is not recom-
mended [4]. Use in patients who do not have AD
results in patients being treated for a disease that
they do not have, and could mean that they do not
receive treatment for the disease that they do have.
2. Conventional diagnostic approaches
While the diagnostic workup of a patient accord-
ing to NIH recommended guidelines may cost ap-
proximately $2000, this is dwarfed by the other costs
of the disease. It is estimated that in the US the cost
of caring for a patient by their family is $12 000 a
year and in a nursing facility in California the aver-
age cost is reported at $47 000 a year, of which the
family typically pays about half. It is estimated that
within 50 years, if unchecked, there may be 14 mil-
lion individuals in the US who may be a¡ected with
AD and will require medical care and possibly insti-
tutionalization [5]. Indeed the frequency of unrecog-
nized dementia could well be of staggering propor-
tions. The Honolulu-Asia aging study reported that
as many as 21% of families of persons considered to
have dementia did not recognize the presence of dis-
ease [6] and a staggering 52% of family members did
not recognize the presence of very mild dementia in
the patient. In total some 60% of the subjects iden-
ti¢ed as having dementia were either not recognized
by their family as such or had not been medically
evaluated for dementia. Studies on the prevalence
of dementia in East Boston [7] also support the con-
cept that dementia is even more prevalent than typ-
ically considered. Were the Honolulu-Asia aging
study frequency of unrecognized dementia broadly
true, this would imply that there are about 1.8 mil-
lion people currently in the US with unrecognized
dementia in addition to the 2 to 4 million cases of
dementia currently acknowledged. There is a great
need, therefore, for ways to enhance our abilities to
identify AD as early and as accurately as possible.
Practitioners are now recognizing the bene¢ts from
an early and accurate diagnosis. However, diagnosis
at the earlier stages of the disease is likely to be less
accurate than after prolonged follow-up. Indeed, one
of the tenets of the criteria used in diagnosis is the
measurement of a gradual cognitive decline over an
extended period. There are two current roles for dif-
ferential diagnosis. The ¢rst is to identify the cause
of the dementing disorder, and to identify whether
the individual is su¡ering from AD or one of the
other 70 causes of dementia or a combination of
dementing disorders. Equally problematical is the
second di¡erential, which is to identify whether the
individual actually has dementia versus the currently
considered normal e¡ects of aging. The distinction
between normal aging, so-called age-related memory
impairment, and dementia is a topic of active current
research. The advent of both biological based diag-
nostic tools, and the forecast of more and better
therapeutic interventions will drive the ¢eld to estab-
lish clearer distinctions. Indeed, the entire concept of
age-related memory impairment may come to be seen
as analogous to the e¡ect of a lack of estrogen in
post-menopausal women. The development of osteo-
porosis, another example of a late-onset disease, may
be normal but it is neither desirable nor inevitable.
There are both pharmacological and behavioral in-
terventions possible to reduce the risk of osteoporo-
sis. In a similar way, the ¢eld of dementia may de-
velop approaches that are used from an early age to
reduce the probability of developing Alzheimer’s dis-
ease, coupled with identifying high-risk individuals
and initiating possible pharmacological interventions
prior to the development of any symptoms. The
management of the populations at various age ranges
and risk categories would involve widespread screens
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and interventions based on the individual’s risk pro-
¢le and age. With the onset of AD symptoms, a
di¡erent set of management tools and pharmacolog-
ical interventions as well as monitoring studies would
be initiated. In this way, the vision of AD over the
next 5^10 years might come to resemble those re¢ned
for the management of disorders such as heart dis-
ease.
The clinical diagnosis of AD requires a history
from the patient and ideally a relative or other care-
giver and results of mental status testing, physical
and neurological examinations, a panel of conven-
tional laboratory tests, and a neuroimaging study
to rule out other causes of dementia. The workup
may include additional laboratory tests in atypical
cases and more detailed psychometric testing and
follow-up to increase the con¢dence of the diagnosis,
especially when a patient presents with mild demen-
tia [8]. The current guidelines recognize an element of
uncertainty in the clinical diagnosis with the use of
the terms ‘possible’ or ‘probable’, with de¢nite AD
reserved for autopsy proven cases. Studies of the ac-
curacy of diagnosis of patients who were evaluated at
dementia specialty research centers and followed
through to autopsy, report rates of agreement of
85^90%. These data should, however, be considered
in context. The patients received extensive workups
and longitudinal monitoring of the cognitive decline.
However, the resources applied to carry out these
evaluations exceed those available to the typical clin-
ical practice. With approximately 500 000 new cases
of dementia a year in the US, the forecast of signi¢-
cant growth in these numbers with the aging popu-
lation, and the decrease in many other diseases of
aging, only very few of these individuals will be for-
tunate enough to be evaluated in a specialized refer-
ral center. Currently approximately 200 new patients
a year are evaluated at each Alzheimer Disease Re-
search Center. Thus with 30 or so centers in the US,
some 6000 patients a year bene¢t from these referral
centers, approximately 1% of the annual caseload.
Diagnosis at early stages of disease is likely to be
less accurate than after prolonged follow-up.
With the advent of symptomatic treatment for
cognitive symptoms of AD and as drugs are devel-
oped to slow the progression of AD, very early diag-
nosis is important to de¢ne the earliest window of
opportunity to apply such treatments. At the earliest
stages of the disease, it is particularly di⁄cult to
document a history of progressive cognitive and
functional decline or to demonstrate de¢cits on cog-
nitive testing. This can raise questions of whether the
symptoms represent age-associated changes or AD.
The increasing prevalence of AD, the limited number
of specialty dementia clinics, the increased necessity
to make an accurate diagnosis to dictate therapy all
further pressure the traditional diagnostic process.
The advent of biomarkers may help to resolve these
dilemmas.
3. Criteria for assessing new diagnostic markers
The search for biological markers of dementia and
AD has been fraught with misunderstandings and
unrealistic expectations against which any putative
marker will fail [9]. There are a number of di¡erent
potential uses for biomarkers in AD evaluation, and
each use could involve a di¡erent marker or set of
markers. First is the use of a marker to distinguish
AD from other causes of dementia. Second is to
distinguish dementia from the non-pathological ef-
fects of aging. Third is to monitor the progress of
the disease after clinical symptoms become apparent.
Fourth will be to have a surrogate to monitor the
e⁄cacy of the forthcoming therapies for AD. Fifth
there is need for markers which are risk factors for
AD and ¢nally identify both the earliest biological
changes occurring in the brain and other changes
that occur as the disease progresses. The concept
that any one marker will ful¢ll all these very di¡ering
requirements to a high degree of sensitivity and spe-
ci¢city is na|«ve. Any individual marker needs to be
assessed by sensitivity, speci¢city, reliability and val-
idity for the type of clinical situation to which it is
meant to appertain. A marker that is poor at distin-
guishing AD from other causes of dementia, could
nevertheless be an excellent marker to monitoring the
progression of the disease process or the response to
therapy. These potential di¡ering uses of biomarkers
need to be kept in mind as information emerges.
Curiously, there appears to be an arti¢cial issue
a£oat, which is the idea that a biomarker or series
of biomarkers will be competitive with the insights of
a trained physician. The more likely scenario is that
the diagnosis and therapy of dementia will come to
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resemble other late-onset disorders such as the pre-
vention and control of coronary artery disease. The
clinical evaluation and biological markers will go
hand in hand to evaluate risk, monitor develop-
ments, plan for and monitor interventions.
There are a number of reasons to consider biolog-
ical markers for AD, which include strengthening the
certainty of the clinical diagnosis, distinguishing AD
from other causes of dementia, and providing a way
to stage the disease and the level of disease activity
and rate of progression. In the future, therapies may
be best monitored by use of surrogate biological
markers. Such an approach may complement the
evaluation of the clinical assessment and could help
streamline the evaluation of future drugs [8].
Biochemical markers for AD have been sought for
many years. The ¢eld is replete with publications of
single studies that could not later be con¢rmed. The
report in 1994 by Scinto et al. on the development of
a pupil dilation test for AD, is one such ¢nding that
at the time stimulated great excitement [10]. A sub-
sequent series of 18 di¡erent studies failed to identify
a useful correlation between pupil dilation with tro-
picamide and AD [11]. As will be discussed below
other approaches have proven robust and reproduci-
ble in many laboratories. With the emergence of the
¢rst biological markers that may stand up to scru-
tiny, a working group from the National Institute of
Aging under the auspices of the Alzheimer’s Associ-
ation was set up to identify the criteria by which a
potential biological marker should be evaluated and
whether any currently identi¢ed markers met the de-
¢ned criteria.
The NIA/AA group identi¢ed a series of ideal cri-
teria for a putative diagnostic test and that any pro-
posed marker should include as many of these ideal
features as possible. In this way, the development of
a standardized approach will aid the development
and evaluation of putative biological markers. Such
an approach will provide a framework by which new
discoveries will be measured to guide further work
and discourage premature claims of diagnostic utility
based on single studies or those carried out by only
one group. The criteria identi¢ed were: ability to
detect a fundamental feature of AD’s neuropathol-
ogy; validated in neuropathologically con¢rmed AD
cases; able to identify AD early in the course of
disease and distinguish AD from other dementias;
reliable; non-invasive; simple to perform; and inex-
pensive. In addition, the group de¢ned a recom-
mended ¢ve steps for establishing a biomarker (see
Table 1). Using these criteria the Working Group
concluded that in early-onset familial AD that it
was appropriate to search for mutations in the pre-
senilin 1, presenilin 2 and amyloid precursor protein
genes. In late-onset and sporadic AD it was con-
cluded that detecting an apolipoprotein E O4 allele
can add con¢dence to the clinical diagnosis. Among
a number of markers evaluated, cerebrospinal £uid
assays measuring levels of beta amyloid 1^42 (AL42)
and tau protein came closest to ful¢lling the criteria
for a useful biomarker.
4. ApoE in Alzheimer’s disease
The ApoE O4 allele is a risk factor for AD rather
than a deterministic gene. Nevertheless, most cases of
AD with onset between the ages of 50^60 have been
attributed to the inheritance of an O4 allele. The ¢rst
link between ApoE and AD was reported in 1993 by
Corder et al. [13]. This study identi¢ed that the risk
for AD increased from 20 to 90% and that the aver-
age age of disease onset decreased with an increasing
number of ApoE O4 alleles. The mean age of onset of
AD was 68 years in those with two O4 alleles, 77
years with one O4 allele in contrast to 85 years in
those with no O4 alleles. The presence of two O4 al-
leles was virtually certain to lead to AD by age 80.
Table 1
Recommended steps in the process of establishing a biomarker
[12]
1. There should be at least two independent studies that
specify the biomarker’s sensitivity, speci¢city, and positive
and negative predictive values.
2. Sensitivity and speci¢city should be no less than 80%;
positive predictive value should approach 90%.
3. The studies should be well powered, conducted by
investigators with expertise to conduct such studies, and
the results published in peer-reviewed journals.
4. The studies should specify type of control subjects,
including normal subjects and those with a dementing
illness but not AD.
5. Once a marker is accepted, follow-up data should be
collected and disseminated to monitor its accuracy and
diagnostic value.
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These original observations have been con¢rmed by
many studies worldwide, and the in£uence of ApoE
in the disease process is now universally accepted.
The O4 allele is considered the strongest risk factor
of late-onset AD next to age, whereas the O2 allele
may be protective or to delay disease onset, which
may amount to the same thing. The ApoE genotype
is perhaps the most important biological marker
identi¢ed for susceptibility to AD to date and ac-
counts for some 40^60% of its genetic component
[14]. Unlike the deterministic mutations in genes
causative of disease, the ApoE alleles are distributed
in all ethnic groups with variations in relative allele
frequencies. While no prediction of whether AD will
occur in an individual based on their allelic makeup
is possible, similarly no ApoE genotype provides an
absence of risk [15]. It is important to note that not
everyone with an O4 allele will get AD and not every-
one who gets AD will have an ApoE O4 allele. In
autopsy series over half of the patients with a con-
¢rmed diagnosis of AD had an O4 allele. Testing for
ApoE has come to be accepted as a valuable adjunct
in the evaluation of a patient with dementia. The
¢nding of an ApoE O4 allele in context with a clinical
workup and suspicion of AD has a demonstrated
positive predictive value of 94^98%. The greatest
utility of ApoE analysis is early in the course of
the disease when an accurate diagnosis can be par-
ticularly challenging.
Two large studies in particular have helped to clar-
ify the initial observations with ApoE. The ¢rst was
a meta-analysis carried out by Farrer et al. [16]
which considered 40 di¡erent studies involving 5930
patients with probable or de¢nite AD, and 8607 con-
trols without AD from a database of more than
15 000 patients and control subjects. The results
showed that the ApoE O4 allele represents a major
risk factor for AD in all the ethnic groups studied,
across all ages from 40 to 90 years and in both men
and women.
The second major study that con¢rmed the value
of ApoE analysis in the evaluation of a person with
dementia utilized autopsy proven diagnoses and was
reported by Mayeux and colleagues [17]. This very
large study followed the earlier publication of a num-
ber of smaller autopsy-based studies where the spe-
ci¢city for the presence of an O4 allele and autopsy
con¢rmation of AD was found to be 100% [18^20].
Given that the O4 allele is a risk factor and not a
causative genetic alteration, these ¢ndings were par-
ticularly surprising. Mayeux and colleagues, in a
study designed to lay to rest the issue of whether
ApoE O4 analysis was useful or not in the diagnostic
workup of a patient with dementia, reported on an
autopsy-con¢rmed study of 2188 patients from 26 of
the AD research centers of the NIH. They found that
the sensitivity of clinical diagnosis alone was 93% at
these specialist centers. However, the speci¢city was
found to be only 55%. The sequential use of ApoE
analysis enhanced the speci¢city of diagnosis from 55
to 84%, an increase in speci¢city of some 53% from
clinical evaluation alone. Adding ApoE analysis in-
creased the positive predictive value of the workup
from 89.6 to 94.2%. Used alone, however, as might
be expected of a marker of trait that is a risk factor,
the sensitivity and speci¢city of ApoE was low. Thus
the use of ApoE testing was unambiguously con-
¢rmed as clinically relevant in patients with dementia
and suspected AD. The ¢nding of an O4 allele in the
context of a dementing disorder has now become an
accepted part of the standard workup of a patient
with dementia. The presence of an ApoE O4 allele in
a person with dementia strongly indicates the pres-
ence of AD as causative of or contributory to the
dementing disorder. The absence of an O4 allele,
however, does not rule out the possibility of AD.
ApoE genotyping is an analysis with the unusual
characteristic of having a strong positive predictive
value but a weak negative predictive value.
ApoE allelic analysis has also been investigated in
the novel area of pharmacogenomics. For probably
the ¢rst time, a genetic marker was evaluated to
identify whether a particular allele caused a height-
ened or diminished response to a pharmacological
agent. Farlow et al. [21] reported on ApoE genotype
in relationship to therapy with tacrine. This is an
agent with a signi¢cant side e¡ect pro¢le, and only
25^50% of treated patients show a bene¢cial clinical
response. This initial study gave uncertain results.
Patients on tacrine and with an O4 allele were found
to be less responsive to therapy than those with other
allele types as a group. However, some individual
patients with an O4 allele did in fact respond very
well to the therapy. Curiously, the patients in the
untreated group who had an O4 allele declined
more slowly than those patients in the untreated
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group who had an O2 or O3 allele. This study sug-
gested a relationship between ApoE genotype and
therapeutic response to cholinesterase therapy, but
further studies are required to clarify some of the
confusing results from this study. In particular, it
would be interesting to determine the relationship
between ApoE genotype and response to donepezil.
Nevertheless, the Farlow study lay the way for strat-
ifying patients in drug trials by ApoE genotype and
potentially other genetic markers, and seeking way to
use genetic analysis to predict response or non-re-
sponse to a particular pharmacologic agent.
5. Tau
Progress in identifying biomarkers of AD recently
has focused on analytes in cerebrospinal £uid (CSF)
that are based on the pathologically altered proteins
found in the brains of patients with AD. Outside of
the neurological community there remains a concern
surrounding the drawing of CSF despite the proven
utility and safety of the procedure. Lumbar puncture
is a minimally invasive outpatient procedure that is
in routine use. Serious complications of lumbar
puncture are extremely rare and the procedure is
usually well tolerated. The most signi¢cant adverse
e¡ect that is normally associated with lumbar punc-
ture is postlumbar puncture headache, which is esti-
mated to occur in 10% of cases in the general pop-
ulation [22]. This is thought to be due to a lowering
of CSF pressure after the lumbar puncture because
of persistent leakage at the puncture site. More re-
cently the use of small-caliber needles has reduced
this risk. Recent studies on postlumbar puncture
headache show a low incidence of headache and
that the procedure is well tolerated. A large study
of 395 elderly patients found that only 2% developed
a headache [23] and a second study found that 92%
of elderly patients agreed to a second lumbar punc-
Table 2
Tau levels in AD versus control groups from 2339 patients
Study AD VAD Depress Frontal PD Non-AD Other AMCON YCON NCON Total
Seubert [22] 76 u 53 H 129
Galasko [25] 82 u 76 Hu 60 H 218
Kanai [26] 45 u 24 H 8 H 77
Motter [27] 37 u 32 H 20 H 89
Vigo-Pilfrey [28] 71 u 25 H 26 H 59 H 181
Munroe [29] 24 u 26 H 13 H 14 H 77
Arai [30] 70 u 96 Hu 19 H 185
Galasko [31] 36 u 9 H 14 H 10 H 69
Riemenschneider [32] 22 u 3 Hu 19 H 44
Tato [33] 23 u 36 H 23 H 82
Jensen [34] 21 u 22 H 8 H 31 Hu 82
Blomberg [35] 18 u 9 H 9 H 36
Rosler [36] 20 u 11 H 12 H 18 H 24 Hu 85
Hock [37] 19 u 18 H 37
Mori [38] 14 u 12 H 1 u 36 H 63
Riemenschneider [39] 39 u 2 H 12 Hu 30 H 83
Rosler [40] 16 u 11 H 10 H 16 H 20 Hu 73
Blennow [41] 44 u 17 u 10 H 11 H 15 H 31 H 128
Skoog [42] 11 u 13 u 2 u 35 H 61
Isoe [43] 9 u 9
Vandermeeren [24] 27 u 19 Hu 110 Hu 51 H 207
Arai [44] 87 u 21 Hu 13 H 17 Hu 39 u 22 H 25 H 224
Vanderstichele [45] 81 u 4 H 15 H 100
Total 892 118 50 15 30 229 250 485 93 177 2339
AD, Alzheimer’s disease; VAD, vascular dementia; Depress, depression; Frontal, frontal lobe dementia; PD, Parkinson’s disease;
Non-AD, other dementing illness (not AD); Other, varied disease states; AMCON, age-matched controls; YCON, younger controls;
NCON, neurological controls (not demented); u, tau elevated; H, baseline; Hu, slight tau elevation.
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ture, demonstrating the general acceptability of the
procedure. While not trivial, lumbar punctures in
elderly demented patients are a relatively straightfor-
ward technique, and the potential information gath-
ered from CSF analysis outweighs the minimal dis-
comfort involved.
The correlation between the abundance of neuro-
¢brillary lesions and the clinical measurements of
dementia stimulated the search to determine whether
this correlation could be measured in CSF. The ini-
tial breakthrough came in 1993 when Vandermeeren
and colleagues [24], using a very sensitive assay that
could measure tau down to 5 pg/ml, found that CSF
tau levels were signi¢cantly elevated in patients with
AD compared to healthy or other disease controls.
Tau is a microtubule-associated protein and the pri-
mary constituent of tangles. Subsequent to this initial
study a surge of recent studies by independent
groups con¢rms that tau levels are increased in the
CSF of patients with AD, compared to age-matched
control subjects.
Over 23 studies have been published in peer-re-
viewed journals from groups around the world show-
ing that tau is elevated in the CSF of AD patients
when compared to either age-related controls or pa-
tients with other neurological diseases. This work
represents testing tau on 2339 subjects involving
892 patients with AD (Table 2). Because of the dif-
ferences in assays and clinical criteria used, it is par-
ticularly surprising that the results are similar and
that every group found an increase in tau levels in
AD patients which is both speci¢c and reasonably
sensitive, with typical measures of 70 and 82% re-
spectively when compared to non-demented control
subjects. The AD patients have also been compared
to patients with a series of other disorders and other
dementias including: vascular dementia, depression,
di¡use Lewy body disease, Pick’s disease, Parkin-
son’s disease, and Creutzfeld^Jakob disease. These
represent a total of some 213 subjects, and no disease
showed a consistent elevation of tau. In general the
studies show that there is no correlation between
Table 3
Correlation of tau and demographics
Study Cog. score Age Duration of AD Age of onset Gender AD genotype
Seubert [22] none none none (ApoE) none
Galasko [31]
Kanai [26] increased
Motter [27] none none none (ApoE) insig.
Vigo-Pilfrey [28] insigni¢cant insigni¢cant
Munroe [29] none insigni¢cant insigni¢cant
Arai [30] insigni¢cant insigni¢cant (ApoE) none
Galasko [25] none none none none
Riemenschneider [32] none none
Tato [33] signi¢cant slight increase
Jensen [34] none (APP) increase





Rosler [40] signi¢cant insigni¢cant
Blennow [41]
Skoog [42] increased (ApoE) none




Arai [44] none none (ApoE, PS-1, ACT)
none
Vandermeeren [24] increase
Vanderstichele [45] none none
Information re£ects terminology used by the authors. Please see individual studies for further information.
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levels of tau and age or gender (Table 3). Further,
there was in general no correlation between levels of
tau and gender, cognitive scores, or duration of dis-
ease. Thus elevation of tau is both a sensitive and
speci¢c marker for AD.
One concern with the measurement of tau levels
was that the measurement may merely represent a
proxy for the detection of neuronal cell loss. How-
ever, absence of elevated tau in a variety of other
degenerative disorders including HIV-associated neu-
rocognitive disorders [46] indicates that the elevation
of tau is not simply correlated with loss of cells. An
exception to this ¢nding is the enormous spike of tau
found in the few months following a stroke, which
are typically far higher than those seen in AD.
The absence of elevated levels of tau in 485 age-
matched controls is of particular interest. The ab-
sence of elevated tau from so many individuals,
some of whom, given the age pro¢le, will soon be-
come demented is in contrast to the ¢nding that tau
is elevated in many of the most mildly demented
patients that can be reliably identi¢ed clinically
[31]. These observations imply that the gross obser-
vation of elevated tau in CSF is a relatively late
occurrence in the disease process and coincident
with the stage of disease at which clinical onset of
symptoms becomes apparent.
6. AL42
The confusion produced by the initial observations
of the absence of a correlation between amyloid lev-
els in CSF and AD were resolved by Motter et al.
[27] who measured both total AL levels, which in-
clude the predominantly present species AL40, and
the amyloidogenic fragment AL42 which comprises
about 5% of total soluble AL. Total AL levels did
not di¡er from AD patients and age-related healthy
controls or disease controls. However, AL42 levels
were signi¢cantly lower in AD patients versus either
control group. These initial ¢ndings were later ex-
tended as well as con¢rmed by independent groups.
Seven studies on AL42 in CSF show a consistent
¢nding that AL42 is reduced in the CSF in the 375
patients studied in comparison to 206 age-matched
controls (Table 4). These studies compared patients
with AD to those with other disorders including vas-
cular, frontotemporal and Parkinson’s dementia. As
with tau, levels of AL42 are not correlated with age or
age of onset of disease. Thus lower levels of AL42 are
not part of the normal aging process but a direct
measurement of a pathological alteration. Similarly
there is no correlation of AL42 with gender, or cog-
nitive test scores. One of the criteria for a potentially
useful diagnostic test is a biologically plausible rela-
tionship of the marker to the pathogenesis of the
disease. Increased production and or deposition of
AL42 is stimulated by all of the known genetic causes
of early-onset AD as well as the presence of an ApoE
O4 allele, and deposits of AL42 as di¡use plaques are
among the earliest detectable neuropathological ab-
normalities of AD. Therefore the AL42 peptide is of
core importance to the disease pathology and the
measurement of CSF AL42 is causally related to the
disease process and not merely a sequelae of the dis-
ease. The decrease of AL42 in CSF is possibly due to
a decrease in the levels of the peptide in the brain
Table 4
AL42 levels in AD versus control groups from 726 patients
Study AD VAD Depress Frontal PD Non-AD Other AMCON NCON Total
Seubert [22] 76 s 53 H 129
Galasko [25] 82 s 76 Hs 60 H 218
Kanai [26] 45 s 24 H 8 H 77
Motter [27] 37 s 32 H 20 H 89
Tamoka [47] 20 s 34 H 54
Vanderstichele [45] 81 s 4 s 15 H 100
Ida [48] 34 s 14 s 11 H 59
Total 375 4 46 76 206 19 726
AD, Alzheimer’s disease; VAD, vascular dementia; Depress, depression; Frontal, frontal lobe dementia; PD, Parkinson’s disease;
Non-AD, other dementing illness (not AD); Other, varied disease states; AMCON, age-matched controls; YCON, younger controls;
NCON, neurological controls (not demented); s, AL42 decreased; H, baseline; Hs, slight AL42 decreased.
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interstitial £uid as the AL42 becomes increasingly in-
soluble and forms the plaque deposits.
In collaboration with six AD research centers, our
group extended its initial observations in a clinical
study involving 82 patients with probable AD, in-
cluding 24 with very mild dementia, 60 cognitively
normal elderly controls and 74 patients with a range
of neurological disorders including dementia [25].
Levels of AL42 and tau were analyzed and compared
across the groups and compared to ApoE genotype
using multiple linear regression. Across the age range
studied, there was no correlation between age and
CSF levels of these analytes. Consistent with the
other studies, levels of AL42 were signi¢cantly lower
and levels of tau were signi¢cantly higher in the AD
group than in either control group. In the AD group,
the level of AL42 was correlated with the presence of
an O4 allele, with the levels being lowest in those
patients homozygous for the O4 allele. Regardless
of whether subjects had none, one or two O4 alleles,
the AD group showed lower AL42 mean levels than
the normal control group. Using both tau and AL42
levels, at a cuto¡ for speci¢city de¢ned as at least
90%, the combined marker analysis provided a sen-
sitivity of 77% for AD. Kanai and colleagues from
three institutes in Japan performed a large study of
236 patients [26] and con¢rmed the combined utility
of tau and AL42. This study combined use of tau and
AL42 provided a diagnostic sensitivity of 71% and a
speci¢city of 83%.
Intriguingly, given that patients with AD have low
levels but not high levels of AL42, while age-related
controls have relatively higher levels of AL42 but may
have low levels of AL42, this could imply that the
lowering of AL42 could signify an early stage of the
disease process. Clearly speculative, however, is that
the measurement of a reduction of AL42 in CSF
could be an early indicator of disease. Once e¡ective
AD therapies are developed, if prospective studies
show that reduction in CSF AL42 is an early indica-
tor of the buildup of pathology, the monitoring of
AL42 CSF levels might be a key marker in the mon-
itoring of the population at risk.
CSF levels of tau and AL42 have each shown good
correlation with AD independently. The combination
together of these markers enhances the value of each
marker independently. In patients suspected of hav-
ing AD, but in whom the clinical diagnosis is uncer-
tain, CSF tau and AL42 can be used to strengthen the
diagnosis. When more than one potential cause of
dementia is suspected, these CSF markers can be
used to help establish that AD is a contributory fac-
tor.
7. Disease causative genes
The major genetic causes of early-onset AD are
now clearly identi¢ed. These are classical autosomal
dominant traits with virtually complete penetrance
and resemble in their e¡ect other conventional
adult-onset disease causative genetic markers such
as Huntington’s disease. The characteristics of the
disease are normally the same in those with early-
onset AD compared to the symptoms and progres-
sion found in late-onset AD. However, a number of
cases have been described indicating that the disease
phenotype of early-onset AD can be broader than
conventional symptoms for AD. Genetic screening
is indicated for individuals showing a family history
combined with dementia combined with atypical
neurodegenerative phenotypes more typical of other
disorders including diseases such as Pick’s disease,
cerebral hemorrhage, or spastic paraparesis [49]. Mu-
tations in the presenilin 1 gene are the most common
de¢ned cause of early-onset familial AD, and are
estimated to account for 30^50% of all cases of
early-onset autosomal dominant familial disease
[50]. The other genetic causes of early-onset familial
AD, mutations in the L amyloid precursor protein
and presenilin 2 (PS2) are considered restricted to a
few families and are not considered at this time of
general utility outside of a research setting.
Our laboratory developed and set up a diagnostic
test for early-onset AD based on sequencing the en-
tire 1401 base coding region of the presenilin 1 gene.
Some authors have indicated that the frequency of
early-onset familial AD may be much less frequent
than is generally acknowledged. Our data show that
out of the ¢rst 195 patients sequenced, 32 (16%) had
a mutation. Given that some of these patients may
be related, by counting only separate mutations, we
found that 18 (9%) di¡erent mutations were identi-
¢ed, each representing a di¡erent lineage. This fre-
quency of mutation identi¢cation (9^16%) in a rela-
tively unselected group is similar to the positive
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frequency found in other genetic-based clinical labo-
ratory tests, and gives reason to believe that muta-
tions in PS1 are responsible for a signi¢cant number
of cases of dementia in the population.
Analysis of PS1 for mutations can be used for
either diagnostic or prognostic information. Once
an a¡ected individual in a family is identi¢ed, the
other members of the family have the opportunity
to be tested prognostically should that be of interest
to them. As a deterministic genetic marker for an
adult-onset disorder, the issues surrounding testing
for mutations in PS1 are similar to those for other
such genetically causative disorders and have been
well de¢ned. These relate primarily to counseling
for those seeking presymptomatic testing, and the
moral and ethical issues surrounding testing of chil-
dren and prenatal testing.
More recently mutations in tau have been shown
to cause a form of frontotemporal dementia, FTDP-
17. The phenotypes caused by these mutations are
still being de¢ned, as is the proportion of frontotem-
poral dementia that is caused by mutations in the tau
gene. Clearly the onward march of genetics is begin-
ning to make inroads into the tortuous ¢eld of de-
mentia. As in other disease areas, it is likely that the
very de¢nitions of the diseases themselves will come
to be based on the speci¢c underlying genetic alter-
ations.
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